Sangeeta Paul

Sangeeta Paul

BSc Pharmacy, MSc Pharmacy, Ph.D. Pharmacology

Sangeeta Paul is a researcher and medical writer based in Gurugram, India. Her academic background is in Pharmacy; she has a Bachelor’s in Pharmacy, a Master’s in Pharmacy (Pharmacology), and Ph.D. in Pharmacology from Banasthali Vidyapith, Rajasthan, India. She also holds a post-graduate diploma in Drug regulatory affairs from Jamia Hamdard, New Delhi, and a post-graduate diploma in Intellectual Property Rights, IGNOU, India.

See more

She has extensive experience in pre-clinical research as a part of her research projects undertaken at the Central Drug Research Institute (CDRI), Lucknow, India. Her research works involved the assessment of phytoconstituents derived from berry-bearing plants on learning and memory-enhancing activity using in vivo and in vitro models.

Sangeeta has co-authored research papers published in reputed journals like Springer Nature and has also served as a reviewer for peer-reviewing manuscripts of reputed journals. She is also a certified Publon Peer Reviewer.

Sangeeta has presented many posters and oral presentations in scientific conferences and attended many scientific workshops. She has worked as a lecturer and research analyst and is passionate about health, secondary research, and medical writing. When she is not working, she enjoys traveling and cooking.

See less

Articles from Sangeeta

Risk of death involving COVID-19 following infection from Omicron relative to Delta

Risk of death involving COVID-19 following infection from Omicron relative to Delta

Distributed lag models to estimate incident rates using concentrations of SARS-CoV-2 RNA from wastewater solids

Distributed lag models to estimate incident rates using concentrations of SARS-CoV-2 RNA from wastewater solids

Protective immunity signatures provided by convalescent plasma for the development of COVID-19 antibody therapeutics

Protective immunity signatures provided by convalescent plasma for the development of COVID-19 antibody therapeutics

Omicron BA. 2 reinfections can occur shortly following BA.1 infection

Omicron BA. 2 reinfections can occur shortly following BA.1 infection

High nasopharyngeal viral load in SARS-CoV-2 Omicron-induced infection

High nasopharyngeal viral load in SARS-CoV-2 Omicron-induced infection

Prevalence of chemosensory loss induced by SARS-CoV-2 Omicron variant in Italy

Prevalence of chemosensory loss induced by SARS-CoV-2 Omicron variant in Italy

Comparative transmission study of SARS-CoV-2 Omicron and Delta variant in England

Comparative transmission study of SARS-CoV-2 Omicron and Delta variant in England

Study measures recovery rate of SARS-CoV-2-induced olfactory loss

Study measures recovery rate of SARS-CoV-2-induced olfactory loss

Surfactant-containing oral mouthwashes target the lipid envelope of SARS-CoV-2

Surfactant-containing oral mouthwashes target the lipid envelope of SARS-CoV-2

SARS-CoV-2 Mpro inhibitor, nirmatrelvir, found to reduce COVID-19 progression and death

SARS-CoV-2 Mpro inhibitor, nirmatrelvir, found to reduce COVID-19 progression and death